List of signals discussed at PRAC since September 2012

European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use - Revision 5

CVMP Interested Parties’ meeting May 2025, European Medicines Agency, Amsterdam, the Netherlands, from 14 May 2025, 17:00 (CEST) to 14 May 2025, 19:00 (CEST)

Human medicines European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan), clopidogrel,acetylsalicylic acid, Date of authorisation: 09/01/2020, Revision: 9, Status: Authorised

PRAC recommendations on signals adopted at the 7-10 April 2025 meeting

Human medicines European public assessment report (EPAR): Ecansya (previously Capecitabine Krka), capecitabine, Date of authorisation: 20/04/2012, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Capecitabine Accord, capecitabine, Date of authorisation: 20/04/2012, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): NeoRecormon, epoetin beta, Date of authorisation: 16/07/1997, Revision: 35, Status: Authorised

Emergency Task Force (ETF) documents

PRAC-ETF considerations on the use of Ixchiq live attenuated virus vaccine against chikungunya